9 research outputs found
Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Standard first-line chemotherapy results in disease progression and death within one year in most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro-oesophageal adenocarcinoma(1-4). Nivolumab plus chemotherapy demonstrated superior overall survival versus chemotherapy at 12-month follow-up in gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in the randomized, global CheckMate 649 phase 3 trial(5) (programmed death ligand-1 (PD-L1) combined positive score >= 5 and all randomized patients). On the basis of these results, nivolumab plus chemotherapy is now approved as a first-line treatment for these patients in many countries(6). Nivolumab and the cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitor ipilimumab have distinct but complementary mechanisms of action that contribute to the restoration of anti-tumour T-cell function and induction of de novo anti-tumour T-cell responses, respectively(7-)(11). Treatment combining 1 mg kg(-1) nivolumab with 3 mg kg(-1) ipilimumab demonstrated clinically meaningful anti-tumour activity with a manageable safety profile in heavily pre-treated patients with advanced gastro-oesophageal cancer(12). Here we report both long-term follow-up results comparing nivolumab plus chemotherapyversus chemotherapy alone and the first results comparing nivolumab plus ipilimumab versus chemotherapy alone from CheckMate 649. After the 24.0-month minimum follow-up, nivolumab plus chemotherapy continued to demonstrate improvement in overall survival versus chemotherapy alone in patients with PD-L1 combined positive >= 5 score (hazard ratio 0.70; 95% confidence interval 0.61, 0.81) and all randomized patients (hazard ratio 0.79; 95% confidence interval 0.71, 0.88). Overall survival in patients with PD-L1 combined positive score >= 5 for nivolumab plus ipilimumab versus chemotherapy alone did not meet the prespecified boundary for significance. No new safety signals were identified. Our results support the continued use of nivolumab plus chemotherapy as standard first-line treatment for advanced gastro-oesophageal adenocarcinoma
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Background First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median overall survival (OS) of less than 1 year. We aimed to evaluate first-line programmed cell death (PD)-1 inhibitor-based therapies in gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma. We report the first results for nivolumab plus chemotherapy versus chemotherapy alone. Methods In this multicentre, randomised, open-label, phase 3 trial (CheckMate 649), we enrolled adults (>= 18 years) with previously untreated, unresectable, non-HER2-positive gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma, regardless of PD-ligand 1 (PD-L1) expression from 175 hospitals and cancer centres in 29 countries. Patients were randomly assigned (1:1:1 while all three groups were open) via interactive web response technology (block sizes of six) to nivolumab (360 mg every 3 weeks or 240 mg every 2 weeks) plus chemotherapy (capecitabine and oxaliplatin every 3 weeks or leucovorin, fluorouracil, and oxaliplatin every 2 weeks), nivolumab plus ipilimumab, or chemotherapy alone. Primary endpoints for nivolumab plus chemotherapy versus chemotherapy alone were OS or progression-free survival (PFS) by blinded independent central review, in patients whose tumours had a PD-L1 combined positive score (CPS) of five or more. Safety was assessed in all patients who received at least one dose of the assigned treatment. This study is registered with ClinicalTrials.gov, NCT02872116. Findings From March 27, 2017, to April 24, 2019, of 2687 patients assessed for eligibility, we concurrently randomly assigned 1581 patients to treatment (nivolumab plus chemotherapy [n=789, 50%] or chemotherapy alone [n=792, 50%]). The median follow-up for OS was 13.1 months (IQR 6.7-19.1) for nivolumab plus chemotherapy and 11.1 months (5.8-16.1) for chemotherapy alone. Nivolumab plus chemotherapy resulted in significant improvements in OS (hazard ratio [HR] 0.71 [98.4% CI 0.59-0.86]; p= 25%) were nausea, diarrhoea, and peripheral neuropathy across both groups. 16 (2%) deaths in the nivolumab plus chemotherapy group and four (1%) deaths in the chemotherapy alone group were considered to be treatment-related. No new safety signals were identified. Interpretation Nivolumab is the first PD-1 inhibitor to show superior OS, along with PFS benefit and an acceptable safety profile, in combination with chemotherapy versus chemotherapy alone in previously untreated patients with advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma. Nivolumab plus chemotherapy represents a new standard first-line treatment for these patients. Funding Bristol Myers Squibb, in collaboration with Ono Pharmaceutical. Copyright (c) 2021 Elsevier Ltd. All rights reserved
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Background First-line chemotherapy for advanced or metastatic human
epidermal growth factor receptor 2 (HER2)-negative gastric or
gastro-oesophageal junction adenocarcinoma has a median overall survival
(OS) of less than 1 year. We aimed to evaluate first-line programmed
cell death (PD)-1 inhibitor-based therapies in gastric,
gastro-oesophageal junction, and oesophageal adenocarcinoma. We report
the first results for nivolumab plus chemotherapy versus chemotherapy
alone.
Methods In this multicentre, randomised, open-label, phase 3 trial
(CheckMate 649), we enrolled adults (>= 18 years) with previously
untreated, unresectable, non-HER2-positive gastric, gastro-oesophageal
junction, or oesophageal adenocarcinoma, regardless of PD-ligand 1
(PD-L1) expression from 175 hospitals and cancer centres in 29
countries. Patients were randomly assigned (1:1:1 while all three groups
were open) via interactive web response technology (block sizes of six)
to nivolumab (360 mg every 3 weeks or 240 mg every 2 weeks) plus
chemotherapy (capecitabine and oxaliplatin every 3 weeks or leucovorin,
fluorouracil, and oxaliplatin every 2 weeks), nivolumab plus ipilimumab,
or chemotherapy alone. Primary endpoints for nivolumab plus chemotherapy
versus chemotherapy alone were OS or progression-free survival (PFS) by
blinded independent central review, in patients whose tumours had a
PD-L1 combined positive score (CPS) of five or more. Safety was assessed
in all patients who received at least one dose of the assigned
treatment. This study is registered with ClinicalTrials.gov,
NCT02872116.
Findings From March 27, 2017, to April 24, 2019, of 2687 patients
assessed for eligibility, we concurrently randomly assigned 1581
patients to treatment (nivolumab plus chemotherapy [n=789, 50%] or
chemotherapy alone [n=792, 50%]). The median follow-up for OS was
13.1 months (IQR 6.7-19.1) for nivolumab plus chemotherapy and 11.1
months (5.8-16.1) for chemotherapy alone. Nivolumab plus chemotherapy
resulted in significant improvements in OS (hazard ratio [HR] 0.71
[98.4% CI 0.59-0.86]; p<0.0001) and PFS (HR 0.68 [98 % CI
0.56-0.81]; p<0.0001) versus chemotherapy alone in patients with a PD-L1
CPS of five or more (minimum follow-up 12.1 months). Additional results
showed significant improvement in OS, along with PFS benefit, in
patients with a PD-L1 CPS of one or more and all randomly assigned
patients. Among all treated patients, 462 (59%) of 782 patients in the
nivolumab plus chemotherapy group and 341 (44%) of 767 patients in the
chemotherapy alone group had grade 3-4 treatment-related adverse events.
The most common any-grade treatment-related adverse events (>= 25%)
were nausea, diarrhoea, and peripheral neuropathy across both groups. 16
(2%) deaths in the nivolumab plus chemotherapy group and four (1%)
deaths in the chemotherapy alone group were considered to be
treatment-related. No new safety signals were identified.
Interpretation Nivolumab is the first PD-1 inhibitor to show superior
OS, along with PFS benefit and an acceptable safety profile, in
combination with chemotherapy versus chemotherapy alone in previously
untreated patients with advanced gastric, gastro-oesophageal junction,
or oesophageal adenocarcinoma. Nivolumab plus chemotherapy represents a
new standard first-line treatment for these patients. Funding Bristol
Myers Squibb, in collaboration with Ono Pharmaceutical. Copyright (c)
2021 Elsevier Ltd. All rights reserved